Leibniz Centre for Tropical Marine Research

FIXX 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys Before May 24th Deadline in Securities Class Action

Retrieved on: 
Saturday, May 14, 2022 - 3:49pm

Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.

Key Points: 
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Homology Medicines should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Tuesday, May 10, 2022 - 6:35am

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, May 24th Deadline Approaching in Securities Class Action

Retrieved on: 
Monday, May 9, 2022 - 5:44pm

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, May 2, 2022 - 9:34pm

Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.

Key Points: 
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Homology Medicines should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, April 28, 2022 - 6:07pm

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, April 28, 2022 - 5:30am

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 25, 2022 - 9:34pm

SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Wednesday, April 20, 2022 - 12:47am

To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

FIXX FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 18, 2022 - 2:24pm

SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Friday, April 15, 2022 - 3:56pm

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.